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Objective: This randomized, placebo-controlled study evaluated the efﬁcacy and safety of a ﬁxed dose
(3 mg/day) and ﬂexible dose (3–15 mg/day) schedule of aripiprazole as augmentation therapy in Japanese
patients with inadequate response to antidepressant therapy (ADT).
Method: During an 8-week prospective treatment phase, patients experiencing a major depressive episode
received clinicians' choice of ADT. Subjects with inadequate response to ADT were randomized to receive
adjunctive treatment with placebo (n¼195), ﬁxed dose aripiprazole (n¼197) or ﬂexible dose aripiprazole
(n¼194) for 6 weeks. The primary efﬁcacy endpoint was mean change in the Montgomery–Åsberg
Depression Rating Scale (MADRS) total score from the end of prospective treatment (baseline) to the end
of randomized treatment.
Results: More than 90% of patients in all treatment groups completed the 6-week double-blind treatment
phase. Mean MADRS total score was improved to a signiﬁcantly greater extent with ﬁxed dose aripiprazole
and ﬂexible dose aripiprazole (10.5 and 9.6, respectively) than with placebo (7.4). Aripiprazole was
well tolerated. The incidence of akathisia observed in the ﬂexible dose group may relate to a higher
prevalence of the CYP2D6*10 allele in Asian populations.
Limitations: Six weeks of adjunctive treatment is insufﬁcient to draw conclusions about the long-term beneﬁts
of aripiprazole. Exclusion of patients with established medical comorbidities does not reﬂect real-world
practice.
Conclusions: Aripiprazole augmentation at a ﬁxed or ﬂexible dose was superior to ADT alone and was
reasonably well tolerated in Japanese patients with inadequate response to ADT.
Clinical trials registration: ClinicalTrials.gov identiﬁer NCT00876343.
& 2013 The Authors. Published by Elsevier B.V.
1. Introduction
Approximately 60% patients with major depressive disorder (MDD)
do not achieve a sufﬁcient response to standard antidepressant
therapy (ADT) and about two-thirds of patients receiving initial
ADT do not achieve timely remission (Fava, 2003; Rush et al., 2006).
An augmentation strategy using atypical antipsychotics for treatment-
resistant depression (TRD) is a widely used and promising approach in
this clinical situation, and is supported by the results of a meta-
analysis (Nelson and Papakostas, 2009) and major treatment guide-
lines, including those of the Canadian Network for Mood and Anxiety
Treatments (Lam et al., 2009) and the American Psychiatric Associa-
tion (2010).
Aripiprazole was the ﬁrst atypical antipsychotic approved by the
United States (US) Food and Drug Administration (FDA) for adjunctive
treatment of MDD in patients showing inadequate response to ADT.
Starting doses of aripiprazole are 2–5mg/day and the recommended
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therapeutic doses range from 5 to 10mg/day. The maximum dose
is 15 mg/day based on results of two large, multicenter, random-
ized, double-blinded, placebo-controlled studies conducted in the US
(Berman et al., 2007; Marcus et al., 2008).
Aripiprazole is approved for use in some Asian countries (e.g.
South Korea and Taiwan), although approval was granted based on
studies conducted in predominantly Caucasian populations
(Berman et al., 2007, 2009; Marcus et al., 2008). To date, no
adequately controlled clinical studies have investigated the efﬁ-
cacy and tolerability of aripiprazole speciﬁcally in Asian patients
with MDD. As genetic/racial variations can cause differences in the
metabolism of antipsychotic medications (Malhotra et al., 2004),
which in turn may impact on treatment response and adverse
event risk, it is important to study new treatment options in
speciﬁc populations.
A lower prevalence of MDD (1–7%) has been reported in Asian
countries such as Japan, Korea, and Taiwan relative to western
countries (Kawakami et al., 2005, Cho et al., 2012), yet suicide rates
in Japan and Korea are among the highest in the world (Värnik,
2012). MDD is an important risk factor for suicide and more than
50% of suicides met the diagnostic criteria for MDD according to a
psychological autopsy study (McGirr et al., 2006).
The Aripiprazole Depression Multicenter Efﬁcacy (ADMIRE)
study was designed to evaluate the efﬁcacy and safety of aripi-
prazole augmentation in Japanese patients with MDD. Consider-
able variability is known to exist among individuals in terms of
their response to antidepressants; optimal doses may differ per
patient and dosages may require frequent adjustments to strike a
balance between efﬁcacy and tolerability. In the current study, a
ﬂexible dose of 3–15 mg/day was set to assess the efﬁcacy of
augmentation therapy in conditions more closely simulating usual
clinical practice. A ﬁxed dose of aripiprazole 3 mg/day was also set
to assess whether this starting dose was effective. Results of the
trial were intended for regulatory submission of aripiprazole
augmentation for treatment of MDD in Japan.
2. Methods
2.1. Patients
Patients eligible for enrollment in the screening phase were
required to be 20–65 years of age who met DSM-IV-TR criteria for
MDD as a primary diagnosis and who had a score ofZ18 on the
17-item Hamilton Depression Rating Scale (HAM-D17; Hamilton,
1960). Patients were also required to have had a major depressive
episode that had lasted Z8 weeks prior to inclusion without
adequate response to 1–3 antidepressant trials of at least 6-weeks'
duration.
Patients were excluded if they had a current Axis I diagnosis of
delirium, dementia, amnestic or other cognitive disorders, schizophre-
nia or other psychotic disorders, bipolar disorders, eating disorders,
obsessive–compulsive disorder, panic disorder, posttraumatic stress
disorder, or substance use disorders; or, a current Axis II diagnosis of
borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic
personality disorders. Patients experiencing hallucinations, delusions,
or any psychotic symptomatology in the current depressive episode
were also excluded. Patients were excluded if they had an Item suicide
(No. 11) score in HAM-D17 ofZ3 and posed a suicidal risk.
In addition, patients were excluded if they had received electro-
convulsive therapy; treatment with aripiprazole in past years; adjunc-
tive antipsychotic (except sulpiride at a doser300 mg/day) or
psychostimulant during the current episode; treatment with mono-
amine oxidase inhibitor within 2 weeks prior to the prospective
treatment phase, and with benzodiazepines (except short-acting
benzodiazepines) within 1 week prior to the prospective treatment
phase; participated in a clinical trial with aripiprazole in past years and
with other investigational product within the past month; had a
history of neuroleptic malignant syndrome, serotonin syndrome, and
seizure disorder; had required hospitalization in the current episode
during the screening phase.
2.2. Study design
This multicenter, randomized, double-blind, placebo-controlled
trial was conducted at 169 sites in Japan between April 2009 and
January 2012, in accordance with the Declaration of Helsinki. Prior to
study entry, all patients provided written informed consent after
receiving explanation of the study procedure and potential risks.
The study consisted of 3 phases. Patients ﬁrst entered a 1–28
day screening phase in which prohibited psychotropic medications
(ADTs, benzodiazepines, and most hypnotic agents) were discon-
tinued. Those patients experiencing a major depressive episode,
which was deﬁned as a total score of Z18 on HAM-D17 at the end
of the screening phase, qualiﬁed for an 8-week, single-blind,
prospective treatment phase. This phase was designed to establish
that patients had an inadequate response to standard ADT before
being randomized to adjunctive aripiprazole or placebo. During
this phase, all patients received single-blind ADT (investigators,
but not patients, knew of the treatment assignment), and adjunc-
tive placebo, so that patients were unaware of transition into the
randomization phase. All patients received ADT in accordance with
current product labeling, based on the investigator's judgment
from the subject's clinical response and tolerability.
Patients meeting the criteria for inadequate response (o50%
reduction in the HAM-D17 total score from baseline to the end of the
prospective treatment phase; a HAM-D17 total score of Z14; or a
Clinical Global Impression-Improvement (CGI-I; Guy, 1976a) score of
Z3 were eligible to enter a 6-week, randomized, double-blind phase
(actual study visits, weeks 8–14), in which participants were ran-
domly assigned in a 1:1:1 ratio to continue the same ADT (no dose
adjustment was permitted) plus either adjunctive placebo, adjunctive
aripiprazole at a ﬁxed dose (3 mg/day), or adjunctive aripiprazole at
a ﬂexible dose (3–15 mg/day).
2.3. Dosing schedule for double-blind treatment
Patients randomized to the aripiprazole ﬂexible dose group
started with a dose of 3 mg/day; investigators could increase the
dose by 3 mg/day once per week to a maximum of 15 mg/day if well
tolerated. Patients assigned to the aripiprazole ﬁxed dose group also
started with a dose of 3 mg/day. If patients did not respond,
investigators could increase placebo tablets once per week to a
maximum of 5 tablets, equivalent to 15 mg/day. Similarly, patients
assigned to the placebo group started with one placebo tablet and, if
patients did not respond, investigators could increase placebo tablets
once per week to a maximum of 5 tablets, equivalent to 15 mg/day.
Dose reduction for tolerability reasons was permitted at any visit. No
dose increase was permitted in the last week of the study.
2.4. Assessments
The primary efﬁcacy endpoint was mean change in the Mon-
tgomery–Åsberg Depression Rating Scale (MADRS; Montgomery
and Åsberg, 1979) total score from the end of the prospective
treatment phase (week 8 visit) to the end of the randomized,
double-blind treatment phase (week 14, last observation carried
forward [LOCF]). A key secondary endpoint was mean change in
the Sheehan Disability Scale (SDS; Leon et al., 1992) score during
the randomized, double-blind phase. The SDS evaluates the extent
to which depression interferes with work, family and social life;
each aspect is scored on a scale from 0 (not at all) to 10 (extreme),
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and a mean score of 0–10 is generated from the individual items.
Other secondary efﬁcacy measures included mean change in the
MADRS total score by week, the CGI-I and CGI Severity of Illness
(CGI-S; Guy, 1976a), and the HAM-D17 total score. Furthermore,
MADRS response and remission rates were assessed. Response was
deﬁned as a reduction in the MADRS total score of at least 50%
relative to the end of the prospective treatment phase. Remission
was deﬁned as a response plus an absolute MADRS total score of
r10. CGI-I response was deﬁned as the proportion of patients
with CGI-I scores of 1 and 2.
Safety was evaluated by monitoring adverse events (AEs), body
weight, vital signs, laboratory parameters, and 12-lead electro-
cardiography. In addition, evaluations of extrapyramidal symp-
toms included changes in the Drug-Induced Extrapyramidal
Symptoms Scale (DIEPSS; Inada, 2009), the Abnormal Involuntary
Movement Scale (AIMS; Guy, 1976b), and the Barnes Akathisia
Clinical Assessment (BARS; Barnes, 1989).
2.5. Statistical analyses
The randomized sample comprised all patients who were
randomized in the double-blind treatment phase. The efﬁcacy
sample included all patients who had received at least one dose
of double-blind study medication and for whom at least one post-
randomization efﬁcacy evaluation had been obtained. The safety
sample included randomized patients who had received at least one
dose of double-blind study medication and for whom at least one
safety evaluation had been obtained. Analyses were conducted
using LOCF data.
The primary efﬁcacy outcome measure, mean change in the
MADRS total score from end of the prospective treatment phase to
end of the double-blind treatment phase, was assessed by analysis
of covariance (ANCOVA) with the score at the end of the prospec-
tive treatment phase as a covariate and treatment as a factor. CGI-S
scores, SDS scores and HAM-D17 total scores were evaluated
using ANCOVA, with the score at the end of prospective treat-
ment phase as a covariate and treatment as a factor. MADRS
response and remission rates, and CGI-I response between the
treatment and placebo groups were compared using Chi-square
tests. The results of all statistical tests were interpreted at the 5%
signiﬁcance level.
3. Results
3.1. Patient disposition
In total, 1388 patients were screened, of whom 1115 were eligible
to enter the prospective treatment phase; 869 patients completed
this treatment phase (Fig. 1). Of these, 283 patients met the criteria
for response during prospective ADT treatment (HAM-D17 improve-
ment Z50%, HAM-D17o14, or CGI-Io3) and did not proceed to the
double-blind treatment phase. Of 586 patients randomized in the
double-blind treatment phase, 195 received adjunctive placebo, 197
received adjunctive ﬁxed dose (3 mg/day) of aripiprazole and 194
received adjunctive ﬂexible dose (3–15 mg/dy) of aripiprazole. The
randomized, double-blind treatment phase was completed by 91–
93% of patients in all treatment groups. Reasons for treatment
discontinuation are provided in Fig. 1.
Treatment groups were well balanced with respect to baseline
demographics and disease characteristics (Table 1). All participants
were Japanese. At the time of randomization to double-blind
treatment, the overall distribution of speciﬁc ADTs was as follows:
sertraline, 38.4%; ﬂuvoxamine, 20.0%; paroxetine, 19.3%; milnaci-
pran, 12.8%; and duloxetine, 9.6%. The distribution was represen-
tative of ADTs selected during the initial prospective treatment
phase and was similar among placebo and aripiprazole treatment
arms (data not shown).
The mean dose of adjunctive aripiprazole in the ﬂexible group at
endpoint was 9.8 mg/day. The distribution of adjunctive aripiprazole
dose at endpoint was as follows: 3 mg/day, 16.5%; 6 mg/day, 20.6%;
9 mg/day, 14.4%; 12 mg/day, 16.0% and 15 mg/day, 32.5%. For patients
in the ﬁxed dose group and placebo group, mean dose equivalents
(based on number of tablets) were 10.1 mg/day and 12.3 mg/day,
respectively.
Completed: 
N=180 (91.4%) 
Completed: 
N=177 (91.2%) 
Completed: 
N=183 (92.2   ) 
Entered prospective treatment phase: 
N=1115 
Screened: 
N=1388 
  Discontinued: N=246 
       Withdrew consent: N=83 
       Lost to follow-up: N=19 
       Adverse events: N=59 
       Poor/Non-compliance: N=8 
       No longer meets study criteria: N=2 
       Other: N=75 
Adjunctive aripiprazole  
3-15mg/day 
N=194 
Adjunctive aripiprazole  
3mg/day 
N=197 
Adjunctive placebo 
N=195 
Discontinued: N=17 
   Withdrew consent: N=4 
   Lost to follow-up: N=2 
   Adverse events: N=7 
   Poor/Non-compliance: N=2 
   Other: N=2 
Discontinued: N=17 
   Withdrew consent: N=4 
   Lost to follow-up: N=2 
   Adverse events: N=8 
   Poor/Non-compliance: N=1 
   Other: N=2 
Discontinued: N=12 
   Withdrew consent: N=3 
   Lost to follow-up: N=3 
   Adverse events: N=2 
   Poor/Non-compliance: N=1 
   Other: N=3 
Responders to initial antidepressant therapy:    
N=283     
Randomly assigned to double-blind treatment: 
N=586 
Fig. 1. Patient disposition.
K. Kamijima et al. / Journal of Affective Disorders 151 (2013) 899–905 901
3.2. Efﬁcacy
Patients who received either the adjunctive ﬁxed dose or ﬂexible
dose of aripiprazole experienced signiﬁcantly greater improvement in
their mean MADRS total score (10.5 and 9.6, respectively) at study
endpoint than patients treated with adjunctive placebo (MADRS total
score, 7.4) (Fig. 2). MADRS response rates at week 6 were signiﬁ-
cantly higher in the adjunctive aripiprazole groups (39.2% for ﬂexible
dose; 42.1% for ﬁxed dose) than in the adjunctive placebo group
(28.2%) (Fig. 3A). Remission rates were also signiﬁcantly higher in the
adjunctive aripiprazole groups (30.4% for ﬂexible dose; 32.5% for ﬁxed
dose) than in the adjunctive placebo group (20.5%) at week 6 (Fig. 3B).
Signiﬁcantly greater improvement in the mean SDS score was
noted with adjunctive aripiprazole (1.03 for ﬂexible dose; 0.96
for ﬁxed dose) compared with adjunctive placebo (0.46) at end-
point (po0.01, Table 2). Signiﬁcant improvements over adjunctive
placebo were observed with both ﬁxed dose and ﬂexible dose
adjunctive aripiprazole in all sub-score items (work/school, po
0.01; social life, po0.01; family, po0.01). Both adjunctive aripipra-
zole regimens also produced signiﬁcantly greater improvements in
CGI-S scores (po0.05), CGI-I response rate (po0.05), and HAM-D17
total score (po0.01) than adjunctive placebo (Table 2).
3.3. Safety and tolerability
3.3.1. Adverse events
During the double-blind phase, 117 (60.0%) patients in the
placebo group, 141 (71.6%) patients in the aripiprazole ﬁxed dose
group, and 151 (77.8%) patients in the aripiprazole ﬂexible dose
group experienced at least 1 AE. AEs experienced at an incidence
of Z5% in either aripiprazole group and at least twice that of the
placebo group are shown in Table 3. The most common AEs in the
aripiprazole groups were akathisia and tremor, and the incidence
was higher in the ﬂexible dose vs ﬁxed dose group (Table 3). The
majority of AEs were mild (aripiprazole ﬂexible dose 59.3%, ﬁxed
dose 54.8%, placebo 48.7%) or moderate (17.0%, 15.7%, 10.8%) in
severity. Serious AEs occurred in 3 patients (1.5%) in the placebo
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Fig. 2. Mean change in Montgomery–Åsberg Depression Rating Scale (MADRS)
total score from baseline in the randomized, double-blind treatment phase (LOCF).
n po0.05; nn po0.01; nnn po0.001 vs adjunctive placebo (ANCOVA). Mean
baseline MADRS total scores: aripiprazole 3–15 mg/day 25.3; 3 mg/day 25.2;
placebo 25.5.
Table 1
Baseline demographic and clinical characteristics of randomized patients.
Characteristics Aripiprazole placebo (n¼195)
3–15 mg/day (n¼194) 3 mg/day (n¼197)
Gender, male, n (%) 101 (52.1) 124 (62.9) 115 (59.0)
Age, mean (SD), years 38.1 (9.6) 39.2 (9.1) 38.7 (9.2)
Weight, mean (SD), kg 62.5 (14.1) 65.1 (14.7) 63.7 (14.2)
Duration of the current episode (mons) 17.5 (26.1) 15.7 (21.6) 15.6 (16.4)
No. of adequate antidepressant trials in the current episode, n (%)
1 trial 119 (61.3) 130 (66.0) 124 (63.6)
2 trials 54 (27.8) 53 (26.9) 49 (25.1)
3 trials 21 (10.8) 14 (7.1) 22 (11.3)
4 trials or more 0 (0) 0 (0) 0 (0)
Depressive episode, n (%)
Single 102 (52.6) 122 (61.9) 113 (57.9)
Recurrent 92 (47.4) 75 (38.1) 82 (42.1)
MADRS total score, mean (SD) 25.3 (7.3) 25.2 (7.2) 25.5(7.4)
Abbreviations: SD¼standard deviation, MADRS¼Montgomery–Åsberg Depression Rating Scale, CGI-S¼¼Clinical Global Impressions-Severity of Illness, HAMD-17¼17-item
Hamilton Depression Rating Scale for Depression.
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Fig. 3. Response rates (A) and remission rates (B) with adjunctive placebo
or adjunctive aripiprazole during the double-blind treatment phase (LOCF).
n po0.05; nn po0.01; nnn po0.001 vs adjunctive placebo group (χ2 test).
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group, 2 patients (1.0%) in the adjunctive aripiprazole ﬁxed dose
group, and 3 patients (1.5%) in the adjunctive aripiprazole ﬂexible
dose group; no deaths were reported.
Discontinuation due to AEs in the double-blind treatment
phase occurred in 2 patients (1.0%) in the placebo group, 5 patients
(2.5%) in the aripiprazole ﬁxed dose group, and 5 patients (2.6%) in
the aripiprazole ﬂexible dose group. Patients who experienced AEs
leading to dose reduction were 6 (3.1%) in the placebo group,
17 (8.6%) in the aripiprazole ﬁxed dose group and 33 (17.0%) in the
aripiprazole ﬂexible dose group.
3.3.2. Extrapyramidal symptoms
Akathisia and AEs related to extrapyramidal symptoms during the
double-blind phase were examined with AIMS, BARS, and DIEPSS.
Mean changes in AIMS total scores did not differ signiﬁcantly
between aripiprazole and placebo groups, and only minimal but
signiﬁcant changes from end of the prospective treatment phase to
study endpoint were noted in BARS Global Clinical Assessment of
Akathisia scores (aripiprazole ﬂexible dose group 0.370.0 vs placebo
group 0.070.0; po0.001). A signiﬁcant difference in the DIEPSS
total score at endpoint (LOCF) was found between placebo group
(0.170.1) and both aripiprazole groups (ﬂexible dose, 0.770.1,
po0.001; ﬁxed dose, 0.370.1, p¼0.042).
The majority of patients with akathisia rated the severity as
either mild (aripiprazole ﬂexible dose 78.9%, ﬁxed dose 75.0%,
placebo 100.0%) or moderate (21.1%, 25.0%, 0.0%). For patients in
the aripiprazole ﬂexible dose group and ﬁxed dose group in whom
akathisia occurred, 29.6% and 10.7% received dose reduction, and
45.1% and 46.4% used an anti-Parkinsonian drug, respectively.
3.3.3. Weight gain and laboratory results
The mean weight change during the double-blind phase was
signiﬁcantly greater in the adjunctive aripiprazole groups (ﬂexible
dose, 1.6370.13 kg, po0.001; ﬁxed dose, 1.6870.13 kg, po0.001)
than in the adjunctive placebo group (0.4470.13 kg) (LOCF). A
statistically signiﬁcant difference was also noted in the proportion of
patients who showed clinically signiﬁcant weight gain (Z7% from the
double-blind baseline; LOCF) (placebo, 1.6%; aripiprazole ﬁxed dose,
8.1%, p¼0.003; aripiprazole ﬂexible dose, 10.4%, po0.001).
There were no clinically meaningful differences between ari-
piprazole groups and placebo group in vital signs, electrocardio-
graphic ﬁndings or laboratory values. Mean change in blood
glucose levels during the double-blind phase did not increased
in the adjunctive aripiprazole groups (ﬂexible dose 0.4 mg/dL;
ﬁxed dose 2.9 mg/dL) and adjunctive placebo group (1.3 mg/
dL). Mean serum prolactin levels for aripiprazole and placebo
groups were within the normal range at baseline and at the end of
the prospective phase. A small reduction in prolactin levels was
noted in the adjunctive aripiprazole groups compared with no
change in the adjunctive placebo group.
Table 3
Adverse events occurring during the double-blind phase.
Adverse event Aripiprazole
3–15 mg/
day
(n¼194)
3 mg/day
(n¼197)
Placebo
(n¼195)
n (%) n (%) n (%)
Akathisia 71 (36.6) 28 (14.2) 8 (4.1)
Tremor 20 (10.3) 14 (7.1) 5 (2.6)
Constipation 15 (7.7) 7 (3.6) 4 (2.1)
Dry mouth 13 (6.7) 10 (5.1) 3 (1.5)
Increased Alanine Aminotransferase 13 (6.7) 14 (7.1) 3 (1.5)
Weight gain 12 (6.2) 8 (4.1) 1 (0.5)
Insomnia 10 (5.2) 8 (4.1) 3 (1.5)
Increased Aspartate Aminotransferase 8 (4.1) 10 (5.1) 1 (0.5)
Increased blood creatine phosphokinase 6 (3.1) 10 (5.1) 0 (0.0)
Occurring at an incidence of 45% in either group and at least twice that of the
placebo group with aripiprazole.
Table 2
Mean change in secondary efﬁcacy outcomes at the end of randomized, double-blind phase (LOCF).
Rating Scalea Aripiprazole Placebo
3–15 mg (n¼194) p value 3 mg (n¼197) p value (n¼195)
SDS mean score , mean (SE)
Double-blind baseline 5.0 (0.1) o0.001c 5.0 (0.1) 0.001c 5.3 (0.1)
Change to Week 6 1.0 (0.1)e 1.0 (0.1) 0.5 (0.1)e
SDS Work/School score, mean (SE)
Double-blind baseline 5.4 (0.2) o0.001c 5.4 (0.2) 0.003c 5.6 (0.2)
Change to Week 6 1.0 (0.1)e 0.9 (0.1) 0.4 (0.1)e
SDS Social Life score, mean (SE)
Double-blind baseline 5.5 (0.2) o0.001c 5.2 (0.2) 0.003c 5.6 (0.2)
Change to Week 6 1.2 (0.1)e 1.1 (0.1) 0.6 (0.1)e
SDS Family score, mean (SE)
Double-blind baseline 4.3 (0.2) 0.003c 4.4 (0.2) 0.003c 4.7 (0.2)
Change to Week 6 0.9 (0.1)e 0.9 (0.1) 0.3 (0.1)e
CGI-I response rateb (%)
At Week 6 50.5 % 0.013d 57.9 % o0.001d 37.9 %
CGI-S score, mean (SE)
Double-blind baseline 4.0 (0.0) 0.033c 4.1 (0.0) o0.001c 4.0 (0.0)
Change to Week 6 0.8 (0.1) 0.9 (0.1) 0.6 (0.1)
HAMD-17 total score, mean (SE)
Double-blind baseline 19.8 (0.3) 0.004c 20.0 (0.3) o0.001c 20.2 (0.3)
Change to Week 6 7.0 (0.4)e 7.6 (0.4) 5.3 (0.4)e
a SDS¼Sheehan Disablity Scale; CGI-I¼Clinical Global Impression-Improvement; CGI-S¼Clinical Global Impression-severity of illness; HAMD-17¼17-item Hamilton
Depression Rating Scale.
b CGI-I response is deﬁned as proportion of patients with CGI-I scores of 1 and 2.
c ANCOVA, with the score at the end of prospective treatment phase as a covariate and treatment as a factor.
d Chi-square test.
e n¼193.
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4. Discussion
This multicenter, randomized, placebo-controlled study
showed that a ﬂexible dose (3–15 mg/day) and ﬁxed dose (3 mg/
day) schedule of aripiprazole as adjunctive therapy to ADT was
more effective than adjunctive placebo and well tolerated in
Japanese MDD patients. To our knowledge, this is the ﬁrst report
showing that aripiprazole as augmentation therapy was effective
in Japanese patients with MDD. Adjunctive aripiprazole was
signiﬁcantly superior to adjunctive placebo in improving depres-
sive symptoms at endpoint and the onset of activity was evident
from Week 1. Furthermore, adjunctive aripiprazole signiﬁcantly
improved SDS total score and all 3 domains (Work/School, Social
Activity, Family Life) compared with placebo. These ﬁndings are
consistent with previous controlled studies of aripiprazole con-
ducted in non-Asian populations in the US (Berman et al., 2007,
2009; Marcus et al., 2008), suggestive of no ethnic differences in
the ability to respond to treatment. This reproducibility of results
may provide support for wider use of aripiprazole augmentation
therapy in general practice in Japan and confer a reliable treatment
for patients with TRD.
Interestingly, the ﬁndings revealed comparable clinical beneﬁts
between the ﬁxed dose (3 mg/day) and ﬂexible dose (3–15 mg/
day) schedule of aripiprazole in our patient population. This is
contrary to what was expected but is supported by other success-
ful clinical experiences of low-dose aripiprazole as an adjunctive
agent for refractory depression in Asian populations (Chen et al.,
2012; Lin et al., 2011; Terao, 2008) but not in Western populations
(Fava et al., 2012; Mischoulon et al., 2012). The CYP2D6*10 allele,
which decreases CYP2D6 enzyme activity, is known to be highly
prevalent in Asian populations but rare in Caucasian populations
(Ji et al., 2002); this may affect the pharmacokinetics of aripipra-
zole in Japanese patients (Suzuki et al., 2011) and impact on
treatment response and risk of AEs.
Akathisia was the most common AE with adjunctive aripipra-
zole treatment. The incidence in the ﬂexible dose group (36.6%)
was somewhat higher than that reported in a pooled analysis of
three randomized, controlled trials in predominantly Caucasian
populations (22.7%) (Pae et al., 2011) and may be a factor of the
abovementioned CYP2D6*10 allele. However, approximately 80%
of patients in the ﬂexible dose group rated their akathisia as mild
in severity and only 1 patient (0.5%) discontinued treatment
because of akathisia. The incidence of akathisia in the ﬁxed dose
group was low at 14.2%. In both aripiprazole groups, akathisia was
managed successfully with the addition of an anti-Parkinsonian
drug or by dose reduction.
Although the incidences of most AEs, including that for akathisia,
were lower in the ﬁxed dose group, it is too early to conclude that
aripiprazole 3 mg/day is the optimal dose for clinical practice in Japan.
It is necessary also to take into account the manner in which acute
titration might affect the efﬁcacy and tolerability of the adjunctive
ﬂexible dose. Further investigation into the clinical proﬁle of aripipra-
zole at various dosage levels is required.
A highly variable and often substantial placebo response rate in
studies of depression has long been recognized (Walsh et al.,
2002), and the list of potential contributing factors is wide and
diverse (Fava et al., 2003). In clinical trials, a high placebo effect
can reduce the likelihood of demonstrating statistical superiority
of antidepressant treatment vs placebo (Dworkin et al., 2005). In
the current study aripiprazole as augmentation therapy to ADT
was shown to be signiﬁcantly more effective than placebo in
Japanese patients with MDD not responding adequately to ADT.
The results replicate those of other large-scale placebo-controlled
studies of aripriprazole in the adjunctive setting (Berman et al.,
2007, 2009; Marcus et al., 2008), all of which have demonstrated
superiority of aripiprazole over placebo.
Some methodological limitations of our study need to be
considered. The 6-week implementation period of augmentation
treatment does not allow conclusions to be drawn about long-
term beneﬁts of aripiprazole and the exclusion of patients with
established medical comorbidities does not accurately reﬂect real-
world practice. Although the manner of titration in the ﬂexible
dose group might be considered controversial, the parallel-group
comparison of the study design has helped us to understand the
efﬁcacy and safety of augmentation therapy with aripiprazole and
has overcome the limitations of the previous controlled studies.
In conclusion, our ﬁndings demonstrate that aripiprazole
augmentation at a ﬁxed dose of 3 mg/day and at a ﬂexible dose
of 3–15 mg/day had an efﬁcacy superior to that of an antidepres-
sant alone and was well tolerated in Japanese MDD patients who
had inadequate response to antidepressant monotherapy.
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